← Eichor
Condition: Advanced Mesothelioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Mesothelioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05188859Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06543069Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/Phase 2 · 12 location(s) · Vivace Therapeutics, Inc · NCT04665206A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 · 15 location(s) · Nuvectis Pharma, Inc. · NCT05873686Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 5 location(s) · Cancer Research UK · NCT05944237Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Phase 1 · 1 location(s) · A&G Pharmaceutical Inc. · NCT05627960A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · SHY Therapeutics · NCT07705334APG-2449 in Patients With Advanced Solid Tumors
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT03917043Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05703854A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic
Phase 2 · 97 location(s) · AstraZeneca · NCT06535607Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Phase 1 · 10 location(s) · InSilico Medicine Hong Kong Limited · NCT06566079Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695A Study of MT027 in Patients with Pleural Malignant Tumors
Phase 1 · 1 location(s) · Suzhou Maximum Bio-tech Co., Ltd. · NCT06726564SW-682 in Advanced Solid Tumors
Phase 1 · 8 location(s) · SpringWorks Therapeutics, Inc., a healthcare company of Merc · NCT06251310SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT05568680A 2-part Phase 1/2 Open-label Trial on ODM-212
Phase 1/Phase 2 · 2 location(s) · Orion Corporation, Orion Pharma · NCT07563738Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study of VET3-TGI in Patients With Solid Tumors
Phase 1 · 7 location(s) · KaliVir Immunotherapeutics · NCT06444815A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/Phase 2 · 81 location(s) · Novartis Pharmaceuticals · NCT04104776A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Phase 1 · 1 location(s) · BridGene Biosciences Inc. · NCT06452160A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.